Novant Health Forsyth Cancer Institute - Bethesda Court
Winston-Salem, NC
Accepting patients
CEVOLUTION
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy
- T Cell Engager (TCE)
- Bispecific Antibody
- FCRH5
- Randomization
- Phase 3
Not yet accepting
DURGA-4
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- CAR T Cell
- BCMA
- CD19
- Randomization
- Phase 3